Company: SION
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0002036042-25-000047
Chunk: 352

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-08-11
Form: 10-Q
Item: Part II, Item 8
Chunk 352
---
 lease expense and amortization of discounts on marketable securities.

For the six months ended June 30, 2024, net cash used in operating activities was $23.3 million  primarily due to our net loss of $20.4 million and changes in operating assets and liabilities of $4.6 million, partially offset by $1.7 million of net non-cash charges, which includes stock-based compensation, depreciation, non-cash operating lease expense and amortization of discounts on marketable securities.

Investing Activities

Net cash used in investing activities was $164.4 million during the six months ended June 30, 2025, which was primarily driven by purchases of marketable securities of $228.0 million, partially offset by maturities of marketable securities of $63.7 million.

Net cash used in investing activities was $152.5 million during the six months ended June 30, 2024, due to purchases of marketable securities.

Financing Activities

Net cash provided by financing activities was $202.1 million during the six months ended June 30, 2025, as compared to $181.4 million during the six months ended June 30, 2024. During the six months ended June 30, 2025, and 2024, the Company closed its IPO and Series C Financing, respectively. 

23

Future Funding Requirements

As of June 30, 2025, we had cash, cash equivalents and marketable securities of $337.3 million. Based upon our current operating plans, we believe that our existing cash, cash equivalents and investments in marketable securities, will be sufficient to fund our operations into 2028. However, our forecast for the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. Additionally, conducting preclinical studies and clinical trials is costly, and the timing of progress and expenses in these studies and trials is uncertain. We will need to raise substantial additional capital in the future.

Our future funding requirements will depend largely on:

•the type, number, scope, progress, expansions, results, costs and timing of, discovery, preclinical studies and clinical trials of our current and future product candidates;

•the costs and timing of manufacturing for our current and future product candidates and commercial manufacturing;

•the costs, timing and outcome of regulatory review of our current and future product candidates;

•the timing and amount of